Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Children With Recurrent, Progressive or Refractory Brain Tumors
NCT02359565Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2015
- Primary completion
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in diffuse intrinsic pontine glioma (DIPG), glioma, ependymoma and 2 more, sponsored by National Cancer Institute. Primary endpoints: Incidence of adverse events at 30 days, Sustained objective response and 1 more. Started Jun 2015; status: active, not recruiting.
02
Drugs
03
Conditions
diffuse intrinsic pontine glioma (DIPG)gliomaependymomamedulloblastomabrain neoplasm
Beyond the preview
Go deeper on NCT02359565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02359565.